Cargando…

Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor

Objectives: To develop and validate a prognostic nomogram based on baseline nutritional and inflammatory parameters for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combination programmed death-1 (PD-1) inhibitor. Methods: This retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jia, Yang, Qi, Jiang, Qi, Gu, Li-Wen, Lin, Huan-Xin, Guo, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574520/ https://www.ncbi.nlm.nih.gov/pubmed/37836546 http://dx.doi.org/10.3390/nu15194262

Ejemplares similares

Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma
por: Zhou, Han, et al.
Publicado: (2020)

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy
por: Yang, Jin-Hao, et al.
Publicado: (2021)

A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma
por: Li, Wang-Zhong, et al.
Publicado: (2021)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Smith, Corey, et al.
Publicado: (2021)

Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma
por: Secondino, Simona, et al.
Publicado: (2023)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: Bian, Jin, et al.
Publicado: (2022)

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

Retracted: A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients
por: Bologna, Marco, et al.
Publicado: (2020)

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study
por: Zheng, Shuo-Han, et al.
Publicado: (2022)

Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study
por: Dong, Huan, et al.
Publicado: (2023)

Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma
por: Yu, Justin, et al.
Publicado: (2021)

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
por: Li, Wenting, et al.
Publicado: (2023)

An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma
por: Chan, Sik-Kwan, et al.
Publicado: (2022)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for de novo Metastatic Nasopharyngeal Carcinoma: A Matched Cohort Study
por: Yang, Zhen-Chong, et al.
Publicado: (2022)

The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy
por: Xia, Wei-Xiong, et al.
Publicado: (2013)

EBV based cancer prevention and therapy in nasopharyngeal carcinoma
por: Cao, Ya
Publicado: (2017)

Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy
por: Li, W.-Z., et al.
Publicado: (2021)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
por: Jin, Ting, et al.
Publicado: (2018)

The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis
por: Liu, Weixing, et al.
Publicado: (2021)

Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV
por: Ahmed, Naveed, et al.
Publicado: (2022)

The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection
por: Guo, Can, et al.
Publicado: (2006)

Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma
por: Ye, Qian, et al.
Publicado: (2021)

Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
por: Liu, Li-Ting, et al.
Publicado: (2019)

The predictive value of pre- and post-induction chemotherapy plasma EBV DNA level and tumor volume for the radiosensitivity of locally advanced nasopharyngeal carcinoma
por: Song, Yang, et al.
Publicado: (2017)

Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy
por: Ruan, Yanyun, et al.
Publicado: (2019)

Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy
por: Yan, Wenbin, et al.
Publicado: (2023)

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial
por: Chen, Si-Yuan, et al.
Publicado: (2023)

Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor
por: Liu, Guo-Ying, et al.
Publicado: (2023)

Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study
por: Sun, Xue-Song, et al.
Publicado: (2019)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

Analysis of Epstein–Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region
por: Dias, Josiane M., et al.
Publicado: (2022)

Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma
por: Yuan, Qi, et al.
Publicado: (2023)

Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer
por: Nilsson, Johan S., et al.
Publicado: (2019)

EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis
por: Yang, Tingting, et al.
Publicado: (2022)

Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues
por: WANG, AILIANG, et al.
Publicado: (2016)

Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
por: Hu, Y.-J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_upn8oei4ii2m3vim1d2nqa4ebb